ClinicalTrials.gg
RecruitingNCT07327684Updated Jan 8, 2026

Photoacoustic/Ultrasound Imaging of Brown Adipose Tissue Activity

An interventional study of Multi-wavelength PA/US imaging scanning and cold exposure and Multi-wavelength PA/US imaging scanning and cold exposure in Insulin Resistance and Metabolic Syndrome, sponsored by Peking Union Medical College Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-08.

Primary conditionMetabolic SyndromeRegistry: Insulin ResistanceReclassifiedWhy we changed it
Registry
Insulin Resistance — the first condition term the registry derived for this study.
ClinicalTrials.gg
Metabolic Syndrome
Why
  1. The study's listed conditions name Metabolic Syndrome, a narrower term within Insulin Resistance.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Peking Union Medical College Hospital · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Registered 6 months after the study started (first participant enrolled May 2025, registered Nov 2025).
  • Started May 2025; still recruiting 1 year 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 89 studies in Metabolic Syndrome with a site in China — 35 open to participants now, 39 under way, 1 of them phase 3. Metabolic Syndrome · China.

Planned enrollment
34th of 50
100 · median 143
Started
2025
with 10 others
No phase
39 of 89
16 open now
Primary completion
2026-12
later than 20 of 38 live
Registered
77th of 89
by date

Among the 89 studies in Metabolic Syndrome with a site in China, this one is the 34th largest by planned enrollment of the 50 interventional ones that give a count, is one of 11 that started in 2025, is one of 39 with no phase, reaches primary completion later than 20 of the 38 other live ones, and was the 77th registered.

Metabolic Syndrome

2,119 studies on the registry are indexed under Metabolic Syndrome; 350 are open to participants now.

Browse Metabolic Syndrome studies →

Open to participants now

35 of the 89 studies in Metabolic Syndrome with a site in China are open now. Recruiting first, the newest first:

29 more — sign in →

All 35 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 234 Metabolic Syndrome studies recruiting now, 70 (30%) set no upper age limit and 135 (58%) stop at 75 or younger; 20 take children under 18; 81 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 89 studies in Metabolic Syndrome with a site in China, or all of them as a file.
02

Study summary

The goal of this study is to develop a novel, non-invasive, real-time photoacoustic imaging (PAI) technology for quantifying brown adipose tissue (BAT) and to investigate the differences in BAT morphology and metabolic function between healthy individuals and patients with metabolic syndrome.

The main questions it aims to answer are:

  1. Can PAI technology quantify BAT metabolic function and establish standardized PAI parameters for BAT assessment?
  2. Can PAI parameters distinguish the BAT characteristics of healthy volunteers from patients with metabolic syndrome?

Both healthy adults and patients diagnosed with metabolic syndrome will be recruited. Participants will undergo PAI scans of BAT region under normal conditions and after cold exposure to assess BAT activation.

The ultimate goal is to validate this radiation-free PAI method as a convenient and effective tool for evaluating BAT metabolism, potentially aiding in early diagnosis and treatment monitoring of metabolic syndrome.

Read the detailed description

Brown adipose tissue (BAT) is a thermogenic organ that plays a beneficial role in whole-body metabolism by burning calories to generate heat. Its activity is inversely associated with obesity, insulin resistance, and metabolic syndrome. A key challenge in advancing BAT research and its clinical translation is the lack of a non-radiative, non-invasive imaging technique suitable for repeated use in both healthy and diseased populations. The current gold standard, [¹⁸F]FDG-PET/CT, involves ionizing radiation, limiting its application in longitudinal studies and healthy volunteer screening.

Photoacoustic imaging (PAI) is an emerging hybrid modality that combines high optical contrast with deep ultrasound penetration. It can uniquely quantify tissue composition by detecting intrinsic contrasts like lipids and hemoglobin, making it ideally suited for assessing BAT's lipid content, blood perfusion and vascular oxygenation, which are key aspects of its metabolic function.

The objectives of this study are:

  1. To develop and technically optimize a non-invasive, real-time PAI protocol for quantitative characterization of human BAT morphology and metabolic function.
  2. To establish a set of standardized, quantitative PAI parameters (e.g., related to blood perfusion, lipid composition, blood oxygen saturation) for BAT assessment.
  3. To compare the baseline PAI parameters of BAT between healthy volunteers and patients with metabolic syndrome.

Both healthy control group and the patient group will be recruited to undergo PAI scans targeting the supraclavicular BAT depots. All scans will be performed under normal conditions and a standardized cold exposure protocol to stimulate BAT activity. Quantitative PAI parameters (e.g., total hemoglobin, lipid concentration, oxygen saturation) will be extracted and compared between the Healthy Control group and the Patient group using appropriate statistical tests.

This study will not only develop a novel PAI technology for BAT imaging but also utilize it to directly investigate a critical biological question: how BAT differs between health and disease. By establishing PAI-based biomarkers that can distinguish these states, this research aims to provide a powerful, radiation-free tool for the early detection of metabolic dysfunction, risk stratification, and objective monitoring of therapeutic efficacy for insulin resistance and related metabolic syndrome.

03

Conditions studied

  • Insulin Resistance
  • Metabolic Syndrome

Browse trials for

Keywords

  • Metabolic syndrome
  • Insulin resistance
  • Brown adipose tissue
  • Photoacousitc imaging
04

In context

Metabolic Syndrome Reclassified

2,119 studies on the registry are indexed under Metabolic Syndrome; 350 are open to participants now.

This study's planned enrollment of 100 is above the median of 60 across 1,574 interventional studies indexed under Metabolic Syndrome.

Browse Metabolic Syndrome studies →

Lead sponsor

Peking Union Medical College Hospital is the lead sponsor of 1,158 studies on the registry; 477 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Compared within Metabolic Syndrome, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Insulin Resistance. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Criteria for Healthy Subjects:

(INCLUSION CRITERIA)

  1. Healthy individuals over 18 years of age.
  2. (BMI) \< 30.
  3. No history of metabolic diseases, rheumatic immune diseases, or cardiovascular and cerebrovascular diseases.
  4. Not currently using any sympathomimetic or sympatholytic drugs.
  5. Non-smoker and does not consume excessive alcohol.

(EXCLUSION CRITERIA)

  1. Weight change > 5% within 3 months prior to enrollment.
  2. BMI ≥ 30.
  3. Diagnosis of metabolic disease, rheumatic immune disease, cardiovascular and cerebrovascular disease, or malignant tumor.
  4. Use of sympathomimetic or sympatholytic drugs within 3 months prior to enrollment.
  5. Smoker or consumes excessive alcohol.
  6. Diagnosis of Raynaud's disease, or intolerance/allergy to cold stimulation.
  7. Currently pregnant, lactating, or menstruating.
  8. to the injection of the radionuclide tracer Fluorodeoxyglucose (18F-FDG) or other conditions unsuitable for PET-CT examination.

Criteria for Patients with Metabolic Syndrome and Insulin Resistance-Related Diseases:

(INCLUSION CRITERIA)

  1. Age between 18 and 60 years.
  2. Must meet 3 or more of the following criteria:

    1. Waist circumference ≥ 90 cm for males, ≥ 85 cm for females.
    2. Fasting blood glucose ≥ 6.10 mmol/L (110 mg/dl) OR 2-hour postprandial blood glucose ≥ 7.80 mmol/L (140 mg/dl) OR previously diagnosed diabetes.
    3. Blood pressure ≥ 130/85 mmHg OR previously diagnosed hypertension and under treatment.
    4. Fasting triglycerides (TG) ≥ 1.7 mmol/L (150 mg/dl).
    5. Fasting high-density lipoprotein cholesterol (HDL-C) \< 1.0 mmol/L (40 mg/dl).
  3. Patients diagnosed with Polycystic Ovary Syndrome (PCOS), defined as meeting two or more of the following criteria and excluding other endocrine diseases that could cause similar symptoms: hyperandrogenism, ovulatory dysfunction, polycystic ovary morphology.

(EXCLUSION CRITERIA)

  1. Diagnosis of Type 1 diabetes or other specific types of diabetes.
  2. Presence of acute diabetic complications or severe chronic diabetic complications.
  3. History of acute or chronic pancreatitis, or pancreatic tumors.
  4. Heart failure, unstable angina, myocardial infarction within the past 12 months, cerebral infarction, severe arrhythmia, or severe hypertension (blood pressure > 180/110 mmHg despite antihypertensive medication).
  5. Severe hepatic or renal dysfunction.
  6. Comorbid malignant tumors or other severe chronic diseases.
  7. Received glucose-lowering therapy within 3 months prior to enrollment OR a total of more than 3 months of glucose-lowering therapy in the past 2 years.
  8. Diagnosis of rheumatic immune diseases.
  9. Diagnosis of Raynaud's disease, or intolerance/allergy to cold stimulation.
  10. Currently pregnant, lactating, or menstruating.
  11. Contraindications to the injection of the radionuclide tracer Fluorodeoxyglucose (18F-FDG) or other conditions unsuitable for PET-CT examination.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

06

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Brown adipose tissue assessment of healthy volunteers based on PA/US imaging

    Establish a non-invasive, real-time PAI method for quantitative characterization of human BAT morphology and metabolic function and evaluate the baseline of BAT PA parameters in healthy population.

    Device: Multi-wavelength PA/US imaging scanning and cold exposure

  • Experimental
    Brown adipose tissue assessment of patients with metabolic syndrome based on PA/US imaging

    Evaluate the BAT PA parameters in patients with metabolic syndrome.

    Device: Multi-wavelength PA/US imaging scanning and cold exposure

Interventions

  • DeviceMulti-wavelength PA/US imaging scanning and cold exposure

    Participants will undergo multi-wavelength PAI scans of BAT region under normal conditions and after 30-60 mins cold exposure to assess BAT activation.

  • DeviceMulti-wavelength PA/US imaging scanning and cold exposure

    Participants will undergo multi-wavelength PAI scans of BAT region under normal conditions and after 30-60 mins cold exposure to assess BAT activation.

07

What researchers measure

Primary outcomes

  1. Change in photoacoustic imaging (PAI)-derived total hemoglobin concentration within brown adipose tissue (BAT) after cold exposure.

    The concentration of total hemoglobin (a.u.) within the BAT region of interest will be measured using a co-registered photoacoustic and ultrasound (PA/US) imaging system. The change (Δ) will be calculated as the value after a standardized cold exposure divide the value at baseline.

    Time frame: Baseline and immediately after a standardized 0.5-1 hour cold exposure procedure

  2. Change in photoacoustic imaging (PAI)-derived lipid concentration within brown adipose tissue (BAT) after cold exposure

    The lipid concentration (a.u.) within the BAT region of interest will be measured using a co-registered photoacoustic and ultrasound (PA/US) imaging system. The change (Δ) will be calculated as the value after a standardized cold exposure minus the value at baseline.

    Time frame: Baseline and immediately after a standardized 0.5-1hour cold exposure procedure.

  3. Change in photoacoustic imaging (PAI)-derived oxygen saturation within brown adipose tissue (BAT) after cold exposure

    The oxygen saturation (in %) within the BAT region of interest will be measured using a co-registered photoacoustic and ultrasound (PA/US) imaging system. The change (Δ) will be calculated as the value after a standardized cold exposure minus the value at baseline.

    Time frame: Baseline and immediately after a standardized 0.5-1 hour cold exposure procedure.

  4. Difference between healthy volunteers and patients with metabolic syndrome in the cold-induced change of photoacoustic imaging (PAI)-derived total hemoglobin concentration within brown adipose tissue (BAT).

    The change (Δ) in total hemoglobin concentration (a.u.) after cold exposure (as defined in Outcome 1) will be compared between healthy volunteers and patients diagnosed with metabolic syndrome.

    Time frame: Through study completion, an average of 24 months.

  5. Difference between healthy volunteers and patients with metabolic syndrome in the cold-induced change of photoacoustic imaging (PAI)-derived lipid concentration within brown adipose tissue (BAT)

    The change (Δ) in lipid concentration (a.u.) after cold exposure (as defined in Outcome 2) will be compared between healthy volunteers and patients diagnosed with metabolic syndrome.

    Time frame: Through study completion, an average of 24 months

  6. Difference between healthy volunteers and patients with metabolic syndrome in the cold-induced change of photoacoustic imaging (PAI)-derived oxygen saturation within brown adipose tissue (BAT)

    The change (Δ) in oxygen saturation (in %) after cold exposure (as defined in Outcome 3) will be compared between healthy volunteers and patients diagnosed with metabolic syndrome.

    Time frame: Through study completion, an average of 24 months

08

Study locations

1 of 1 sites recruiting
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for Dec 2026, 19 months after the start.

Of 627 non-industry interventional studies with no phase under Metabolic Syndrome, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 41. This study's planned 19 months is close to that.

Counting every sponsor, half of 677 studies reached it within 20 months; a quarter within 9 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 23, 2025
First posted
Jan 8, 2026
StartActual
May 22, 2025
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2027
Last update
Jan 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07327684
Responsible party
Sponsor
First posted
Jan 8, 2026
Start date
May 22, 2025
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Jan 8, 2026

Study contacts

Meng Yang, Doctor
Contact
yangmeng_pumch@126.com
+8601060155493

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion